Immunomedics Announces Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan in Patients With Pancreatic Cancer

Immunomedics (Nasdaq: IMMU ), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced first patient dosing in the Company's Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan. The PANcreatic Cancer